New flu prevention drug faces off against tamiflu in hospital trial

NCT ID NCT07236814

Recruiting now Prevention Sponsor: Capital Medical University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether two antiviral drugs—suraxavir marboxil and oseltamivir (Tamiflu)—can prevent flu from spreading to uninfected roommates of flu patients in hospitals. About 384 people will take one of the drugs or a placebo for 5 days. Researchers will track how many get the flu to see which approach works best.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Suraxavir marboxil and oseltamivir
What this could lead to: If successful, this could provide a new option to prevent flu transmission in hospitals, reducing outbreaks among patients and staff.
What could go wrong: This is a single trial with 384 participants, so results may not apply broadly. The drugs may cause side effects or prove no better than placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INFLUENZA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

influenza

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INFLUENZA

Contacts and locations

Locations

China-Japan Friendship Hospital
RECRUITING

Beijing, Beijing Municipality, China
China-Japan Friendship hospital, Beijing, Beijing
NOT_YET_RECRUITING

Beijing, Beijing Municipality, 100029, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.